Peking University Cancer Hospital & Institute, ICU Department, Key Laboratory of Carcinogenesis and Translational Research, Beijing, China.
Peking University Cancer Hospital & Institute, ICU Department, Key Laboratory of Carcinogenesis and Translational Research, Beijing, China.
Braz J Anesthesiol. 2022 Mar-Apr;72(2):228-231. doi: 10.1016/j.bjane.2021.02.032. Epub 2021 Mar 20.
The aim of this study was to analyze risk factors for failure of subclavian vein catheterization.
A retrospective analysis of 1562 patients who underwent subclavian vein puncture performed by the same experienced operator at Peking University Cancer Hospital from January 1, 2016 to January 1, 2019 was conducted. The success or failure of subclavian vein catheterization was registered in all cases. Various patient characteristics, including age, gender, body mass index (BMI), preoperative hemoglobin, preoperative hematocrit, preoperative mean corpuscular hemoglobin concentration (MCHC), preoperative albumin, preoperative serum creatinine, puncture needles from different manufacturers and previous history of subclavian vein catheterization were assessed via univariate and multivariate analyses.
For the included patients, landmark-guided subclavian vein puncture was successful in 1476 cases and unsuccessful in 86 cases (success rate of 94.5%). Successful subclavian vein catheterization was achieved via right and left subclavian vein puncture in 1392 and 84 cases, respectively. In univariate analyses, age and preoperative hemoglobin were associated with failure of subclavian vein catheterization. In a multivariate analysis, aged more than 60 years was a risk factor while the central venous access with Certofix® was associated with an increased rate of success (p-values of 0.001 and 0.015, respectively).
This study has demonstrated that patient aged more than 60 years was a risk factor for failure of subclavian vein catheterization while the central venous access with Certofix® was associated with an increased rate of success.
本研究旨在分析锁骨下静脉置管失败的危险因素。
回顾性分析了 2016 年 1 月 1 日至 2019 年 1 月 1 日期间由同一位经验丰富的医生在北京大学肿瘤医院进行的 1562 例锁骨下静脉穿刺患者的资料。所有患者均记录锁骨下静脉置管的成功或失败情况。通过单因素和多因素分析评估了患者的各种特征,包括年龄、性别、体重指数(BMI)、术前血红蛋白、术前血细胞比容、术前平均红细胞血红蛋白浓度(MCHC)、术前白蛋白、术前血清肌酐、来自不同制造商的穿刺针以及既往锁骨下静脉置管史。
对于纳入的患者,1476 例患者采用路标引导下锁骨下静脉穿刺成功,86 例(成功率为 94.5%)失败。右侧和左侧锁骨下静脉穿刺分别成功 1392 例和 84 例。单因素分析显示,年龄和术前血红蛋白与锁骨下静脉置管失败相关。多因素分析显示,年龄大于 60 岁是危险因素,而使用 Certofix®进行中心静脉置管与成功率增加相关(p 值分别为 0.001 和 0.015)。
本研究表明,年龄大于 60 岁的患者是锁骨下静脉置管失败的危险因素,而使用 Certofix®进行中心静脉置管与成功率增加相关。